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Abstract
Background: Matrixmetalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases which are
involved in angiogenesis, tumor invasion and metastatic formation. Up to date, the prognostic relevance of MMPs
in serum of patients with colon cancer remains unknown. Thus, we wanted to assess an expression pattern of
MMPs in a homogenous cohort of colon cancer patients to assess their potential as prognostic biomarkers.
Methods: Differences in the expression pattern of MMP7, MMP10 and MMP12 in 78 serum specimens of patients
with an adenocarcinoma of the colon and serum specimens of a healthy control group were assessed using
Luminex-100 technologies. Subsequently, we correlated these results with histopathological and clinical data of the
patients.
Results: Luminex based expression analysis revealed a significant overexpression of MMP7 and an overexpression
of MMP10 and MMP12 in the sera of colon cancer patients compared to the healthy control group. Patients with
vascular invasion showed a significantly higher MMP12 expression than V0-staged patients. Moreover
overexpression of MMP7, MMP10 and MMP12 in colon cancer patients´ sera displayed a significantly impaired
overall survival. Multivariate analysis revealed high MMP10 serum levels to be an independent adverse prognostic
marker in colon cancer patients.
Conclusions: Expression patterns of MMP7, MMP10 and MMP12 in colon cancer patients´ sera are different
compared to serum specimens of healthy individuals. Furthermore, overexpression of MMP7, MMP10 and MMP12 in
colon cancer patients´ sera correlates with a dismal prognosis and may help to stratify patients into different risk
groups.
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Background
Colorectal cancer (CRC) is one of the most prevalent
cancer entities and the second leading cause of cancer-
related death in the western world [1, 2]. For all stages
of CRC the 5-year survival rate is about 60 % [3]. Sur-
vival depends strongly on the histological stage with
favorable survival rates in stage I and II whereas the out-
come drastically decreases with lymph node positivity or
distant metastases [4]. Adjuvant chemotherapy in ad-
vanced stages improves survival rates heavily, but with
the restrictions of general cytotoxity [5, 6]. It is known
that a percentage of patients is either under- respectively
overtreated due to the decision of adjuvant chemother-
apy referring current clinical guidelines [7]. Therefore
individualized and tailored therapeutic strategies have
turned into focus. Hence other predictive markers then
eg. Dukes stage which influence tumor progression and
survival were investigated like - to name only few - micro-
satellite instability or cyclooxygenase-2 expression with
the aim to proceed a step towards new therapeutic strat-
egies additionally to chemo- and/or radiotherapy [8, 9].
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Matrixmetalloproteinases (MMPs) comprise a family of at
least 25 secreted and cell surface zinc-dependent endo-
peptidases involved in tumor progression, angiogenesis,
invasion of surrounding tissue and metastatic formation
and evasion of the immune system [10]. They are capable
to degrade all components of the extracellular matrix and
even non-matrix proteins, necessarily needed for tumor
invasion and metastatic spread [11, 12]. According to their
substrate specificity or additional structural domain they
are divided into subgroups like Collagenases, Gelatinases,
Stromelysins, Matrilysins and Membrane-type MMPs.
Synthesized as inactive zymogens, they become functional
by proteolytic removal of the propeptide prodomain [13].
The activity of MMPs is regulated by differential expres-
sion and post-translational processes. Activating factors
include transcription factors such as LEF-1 (lymphoid en-
hancer binding factor-1) or ß-catenin, other MMPs, serin
proteinases, cytokines and growth factors [10, 13]. Coun-
terparts in terms of expressional inhibition are the tissue
inhibitors of matrixmetalloproteinases (TIMPs), RECK
(reversion-inducing cysteine-rich protein with Kazal mo-
tifs), α2-Macroglobulin or Thrombospondin [14–16].
Upregulation of several MMPs including MMP7,
MMP10 and MMP12 in cancerous tissue and adverse
association with survival has been evaluated likewise
in colorectal cancer [17, 18]. Moreover secretion of
MMPs into the bloodstream is proposed [19]. However
prognostic impact of MMP expression in colorectal can-
cer patients´ sera has only been assessed partially. In this
study we have chosen three MMPs namely MMP7,
MMP10 and MMP12 for investigation. However, to our
knowledge until now there is no study assessing serum
MMP10 and MMP12 level in a homogenous collective of
colon cancer patients’ sera in regard to overall survival.
The prognostic impact of MMP7 serum level in advanced
colorectal cancer has already been evaluated before [20].
Therefore assessment of serum MMP7 level serves as a
validation for underlining the representative study collective
of patients. Hence, we investigated multiplex bead-based
immunoassay-technology measuring MMP7, MMP10 and
MMP12 serum level in a homogenous collective of 78
patients suffering from colon cancer and a healthy control
serum group to assess presumed differences in expression
pattern and correlations with clinicopathological character-
istics and survival.
Methods
Patients
Serum samples of 78 patients with primary adenocarcin-
oma of the colon were included in our current study.
Patients received surgical treatment at the Department of
General, Visceral, and Transplantation Surgery, University
of Heidelberg, Germany between September 2007 and
January 2012. Serum specimens of 38 healthy individuals
without any known comorbidities served as control serum
group. A written informed consent of all patients and
healthy donors was obtained and the study was approved
by the ethics committee of the University of Heidelberg.
Clinical data included gender, date of birth, age at surgery,
size, tumor location, histopathological diagnosis including
TNM classification and UICC-stage, R-classification, grad-
ing, adjuvant chemotherapy, postoperative complications
and overall survival (time from operation up to death or
last follow up). Median follow up time was 901 ± 469 days
(range: 6–1980 days).
Tissue material and preparation
Patients´ sera were obtained during surgery and imme-
diately stored at −80 °C. Likewise, healthy serum sam-
ples were immediately stored at −80 °C after removal.
Total protein concentration was measured using Pierce®
BCA Protein Assay Kit (Thermo Fisher Scientific Inc,
Rockford, IL, USA) and Infinite 200® PRO Reader (Tecan
Group Ltd., Männedorf, Switzerland) according to the
manufacturer’s protocol. Magellan™ Data Analysis Software
(Tecan Group Ltd., Männedorf, Switzerland) was taken for
analysis of these data. All serum samples were diluted to a
concentration of 0.1 μg/μl of total protein.
Luminex based multiplex assay
Serum samples for the detection of MMP7, MMP10
and MMP12 were processed using Milliplex MAP
Human MMP Assay Kits (Merck Millipore, Millipore
Corporation, Billerica, MA, USA) according to the
manufacturer’s protocol. The exact concentration of these
markers were detected in each sample by Luminex 100™
reader (Luminex Corporation, Austin, Texas, USA).
Statistics
Statistical analysis of the data and calculations were
conducted with Excel 2010 (Microsoft Corporation,
Redmond, WA) and SPSS version 21 (SPSS, IBM Cor-
poration, Armonk, NY).
Wilcoxon-signed rank test was used to determine dif-
ferences in the expression pattern. Expression bars were
presented using mean concentration [pg/ml] + SEM.
Kaplan-Meier method was employed to estimate cancer
related survival. Differences between the survival curves
were evaluated by log-rank test. For survival analysis
Cox proportional hazards model was taken to calculate
survival related hazard ratios. Multivariate analysis was
performed using Cox proportional hazards regression
including the following covariates: age, gender, UICC
stage, TNM-classification, R-Stage, adjuvant chemother-
apy, anastomotic leakage and relative serum expression
of MMP7, MMP10 and MMP12 in colon cancer pa-
tients´ sera vs. sera of healthy control serum group. The
comparison of clinical parameters and relative serum
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expression of MMPs was assessed using the Mann–
Whitney-U-Test and the analysis of variance (Anova)
with the post-hoc Tukey’s test. Contingency table analysis
was performed using the Pearson’s chi-square test. Results
were considered significant at a p-value less than 0.05.
Results
Patients’ characteristics
78 patients suffering from adenocarcinoma of the colon
were included into the study (Table 1). Median age at
the time of operation was 63 years. 28 patients died dur-
ing follow-up. Mean overall survival of all patients was
44.2 months.
Each patient underwent colon cancer surgery accord-
ing to the localization of the tumor: 28 patients had
right colectomy, 13 extended right colectomy, 1 had ex-
tended left colectomy, 9 left colectomy, 19 underwent
sigmoidectomy, 6 patients underwent high anterior rec-
tum resection, 2 patients had subtotal colectomy.
At the time of diagnosis 23 patients were classified
M1, 55 patients as M0. Patients with a metastatic disease
(M1) had a significantly shortened overall survival (p =
0.01). The mean overall survival for stage M0 patients
was 46.7 months whereas it was 36.6 months for pa-
tients with distant metastases (Table 1).
Expression of MMP7, MMP10 and MMP12 in colon cancer
patients´ sera and sera of healthy individuals
The expression of MMP7, MMP10 and MMP12 were
determined in serum samples of 78 colon cancer
patients and 38 serum samples of healthy individuals
using Luminex 100™ technology. Case numbers vary
between different MMPs due to technical measurement
procedures.
MMP7 displayed a significantly higher expression in
the sera specimen of colon cancer patients in compari-
son with healthy control serum group (p = 0.003)
(Fig. 1a). Similarly, we observed a higher abundance of
MMP10 (p = 0.128) (Fig. 1b) and MMP12 (p = 0.544)
(Fig. 1c) in colon cancer patients` sera as compared to
serum specimens of healthy individuals.
The analysis of MMP7, MMP10 and MMP12 expres-
sion regarding clinicopathological characteristics is
shown in Table 2. For MMP7 we could observe signifi-
cant differences in the expression level regarding gender
(p = 0.049), age (p = 0.013) and tumor site (p < 0.001).
MMP10 displayed a significant expressional difference
compared to patients age (p = 0.003). As for MMP7 we
could observe a significant difference of MMP12
expressional level compared to patients’ gender (p =
0.004). Only for MMP12 we could assess a significantly
higher expression in patients with vascular invasion
(V1-stage) compared to V0-staged patients (p = 0.018)
(Table 2). Clinicopathological characteristics of the
patients compared to relative serum expression of
MMP7, MMP10 and MMP12 (each <2 and ≥2) are
shown in Additional file 1.
Taken together our results propose that MMP7,
MMP10 and MMP12 are increased in sera of colon
Table 1 Correlation of clinical parameters with overall survival;
na = not available
Patient
characteristics
Number of
patients
(n = 78)
Mean overall
Survival
(months)
p-value
Gender 0.37
Male 54 43.07
Female 24 49.62
Age at operation 0.514
<median = 64 years 37 43.82
≥ median = 64 years 41 42.68
Anastomotic leakage 0.841
Yes 7 50.10
No 71 44.42
T-Stage 0.495
T1 2 na
T2 8 32.8
T3 54 40.04
T4 14 38.28
N-Stage 0.08
N0 30 49.18
N1 30 37.82
N2 18 41.79
M-Stage 0.01
M0 55 46.69
M1 23 36.55
Occurrence of liver metastases 0.002
Liver metastases (synchronous
and metachronous)
26 35.53
No liver metastases 52 51.51
Resection margin status 0.121
R0 68 45.98
R1 4 35.25
Rx 6 29.02
Grading 0.708
G1 0
G2 54 43.55
G3 23 45.97
Data not available 1
Adjuvant chemotherapy 0.083
Yes 47 40.66
No 31 44.20
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cancer patients when compared to healthy donors and
MMP12 seems to play a role in vascular invasion.
Impact of MMP expression on overall survival
After having confirmed differences in the expression of
MMP7, MMP10 and MMP12 concentrations in colon
cancer patients´ serum samples and serum samples of a
healthy control group we correlated these results with
patients’ overall survival. For this purpose, the quotient
of MMP expression in colon cancer patients´ sera versus
expression in sera of healthy individuals was calculated,
and relative serum expression (serum expression of
colon cancer patients/ serum expression of control
serum group) of <2 and ≥2 was then correlated with
overall survival [21].
Consistently, a relative serum expression ≥2 (serum
expression of colon cancer patients/ serum expression of
control serum group) of MMP7 (HR: 2.8 [95 % CI: 1.1–6.8],
p= 0.02), MMP10 (HR: 2.6 [95 % CI: 1.2–5.9], p= 0.015)
and MMP12 (HR: 2.9 [95 % CI: 1.1–7.8], p = 0.025) cor-
related with a significantly shortened overall survival
(Fig. 2a-c). Strikingly, multivariate analysis revealed that
an increased relative serum expression of MMP10 is an
independent prognostic marker for impaired overall
survival in colon cancer patients (Table 3).
Discussion
The present investigation yielded MMP7, MMP10 and
MMP12 serum levels in a homogenous group of colon
cancer patients to be adverse prognostic molecular markers
Fig. 1 Expression analysis of MMP7, MMP10 and MMP12 in colon cancer patients´ sera and sera of healthy individuals. Expression of (a)
MMP7 (n = 76 respectively 37 patients) (p = 0.003) was significantly underexpressed, expression of (b) MMP10 (n = 76 respectively 38
patients) and (c) MMP12 (n = 73 respectively 32 patients) was reduced in colon cancer patients´ sera as compared to control serum
group. Bars represent mean quantitative amount of each particular MMP [pg/ml] + SEM. ** p = 0.003
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exerting valid multiplex bead-based immunoassay - tech-
nologies. Strikingly, in multivariate analysis, we could pro-
vide evidence that MMP10 is an independent prognostic
marker for impaired overall survival. To our knowledge we
are the first to demonstrate the influence of serum MMP10
and MMP12 on colon cancer patients´ survival.
MMPs are essential regulators facilitating tumor en-
hancing processes including tumor growth, migration,
invasion, apoptosis, angiogenesis as well as immune-
escape mechanisms [10, 22, 23]. Elevated level of several
MMPs could be proven in a variety of cancer entities
[24–26]. Description of upregulation of several MMPs -
among them MMP1,2,3,7,9,10,11,12,13 - in cancerous
tissue of colorectal cancer patients is common [27–29].
Moreover for colorectal cancer an association of MMP
upregulation with advanced Dukes´stage, more infiltra-
tive phenotype, occurrence of metastatic lesions and un-
favorable prognosis was observed [27, 28, 30]. Influxing
of MMPs into the bloodstream was verified indicating
their role as potential prognostic blood-biomarker [31].
Table 2 Overview of clinical parameters and relative serum expression of MMP7, MMP10 and MMP12
Patient Characteristics N Median relative serum expression
MMP7 p MMP10 P MMP12 p
Gender 0.049 0.138 0.004
Male 51 1.21 1.22 1.19
Female 24 0.97 0.95 0.88
Age at operation 0.013 0.003 0.253
<median = 64 years 37 0.95 0.95 1.16
≥ median = 64 years 38 1.2 1.36 1.03
T-Stage 0.582 0.957 0.481
T1 2 0.86 0.9 0.42
T2 8 0.92 1.13 1.11
T3 53 1.08 1.13 1.07
T4 13 1.24 1.22 1.19
N-Stage 0.806 0.074 0.301
Node negative 29 1.06 1.22 1.0
Node positive 46 1.16 0.99 1.14
M-Stage 0.244 0.603 0.087
M0 55 1.06 1.13 1.0
M1 23 1.26 1.13 1.19
L-Stage 0.629 0.085 0.593
L0 61 1.06 1.18 1.06
L1 14 1.25 0.81 1.14
V-Stage 0.067 0.321 0.018
V0 69 1.06 1.13 1.06
V1 6 2.41 1.86 1.32
Micro satellite stage 0.053 0.845 0.844
MSS 5 0.68 0.76 0.47
MSI 2 1.16 0.95 1.01
Tumor site <0.001* 0.76 0.758
Coecum 17 0.98 1.22 1.16
Colon ascendens 14 1.11 0.88 0.78
Right colon flexure 6 1.28 1.32 1.13
Colon transversum 3 1.37 0.86 1.0
Colon descendens 5 2.12 2.16 1.29
Colon sigmoideum 30 0.96 0.99 1.14
*In ANOVA p < 0.001, the post-hoc Tukey’s test showed a significant difference between colon descendens and coecum, colon ascendens and right colon flexure
(p < 0.001; p < 0.001; p = 0.007, respectively)
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Our results indicate pro-tumorigenic effects of overex-
pressed MMP7 in colon cancer patients´ sera compared
to serum samples of a healthy control group resulting in
significantly adverse overall survival. Recent studies have
shown that MMP7 is overexpressed in colorectal cancer
tissue in comparison to normal mucosa [31, 32]. Fur-
thermore, high expression of MMP7 in colorectal cancer
samples exhibits tumor promoting roles in terms of cor-
relation with higher Dukes´stage, lymph node positivity,
poor differentiation and metastases. Besides, impaired
overall survival appears in patients with colorectal tu-
mors expressing high levels of MMP7 [33, 34]. In con-
sistence with our results, increased serum levels of
MMP7 and correlation to worse overall survival in colo-
rectal cancer has been reported [20, 31]. In addition to
this, correlation of elevated serum MMP7 with advanced
Dukes´ stage and prediction of recurrence in colorectal
cancer patients was assessed reflecting higher MMP7
release through tumoral cells due to a higher tumor load
[31, 35]. Oncogenic functions of MMP7 rely on different
interactions between tumor cells, tumor microenviron-
ment and immune system [20]. In contrast to other
MMPs, MMP7 is mainly secreted by cancer cells and
activated through cytokines or other MMPs, which are
released by tumor stromal cells. This intercellular cross-
talk between cancer cells and the tumor microenviron-
ment results in increased tumor growth and invasion
[10, 36]. Moreover, MMP7 enhances immune escape
mechanisms by blocking lymphocyte cytotoxicity. This
immunsuppressive effect is mediated by the cleavage of
CD95/CD95, leading to an escape of the immunosurveil-
lance, decreased apoptosis and chemotherapy resistance
[20, 37, 38]. These tumor promoting functions of MMP7
are in good accordance with our clinical results and may
indicate that a high abundance of serum MMP7 is a sur-
rogate marker for a more aggressive tumor type.
Intriguingly, we were able to show that elevated levels
of MMP10 in colon cancer patients´ sera are related to
an adverse overall survival by univariate and multivariate
analysis. As for MMP7 for MMP10 overexpression in
colorectal cancer specimen is described [27, 39]. How-
ever, no correlation of elevated tumoral MMP10 level
with Dukes´ stage, hepatic metastatic lesions or venous
invasion could be proven [27]. Until now, there is no
study which reports that overexpression of MMP10 in
colon cancer patients´ sera is correlated with survival.
Fig. 2 Correlation of relative MMP serum expression (serum/control serum) and overall survival in univariate analysis. An expression ratio
serum/control serum ≥2 was defined as increased expression. Overall survival was significantly impaired in patients with increased relative
serum expression of (a) MMP7 (HR: 2.8 [95 % CI: 1.1–6.8], p = 0.02) (b) MMP10 (HR: 2.6 [95 % CI: 1.2–5.9], p = 0.015) and (c) MMP12
(HR: 2.9 [95 % CI: 1.1–7.8], p = 0.025). CI = Confidence interval, HR = Hazard ratio
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Yet, the protumorigenic functions of MMP10 have been
well described. Due to stimulation and synergistic effects
of other oncogenes like S100A4 (S100 calcium binding
protein A4), MMP10 stimulates cell growth and invasion
and exerts antiapoptotic properties in vitro [40, 41].
Moreover, in combination with PAI −1 (Plasminogen ac-
tivator inhibitor) and Plasmin, MMP10 contributes to
angiogenesis [42]. These tumor-promoting effects of
MMP10 may explain, why high expression of MMP10 in
sera of patients with colon cancer is associated with a
dismal prognosis. Nevertheless evidence likewise exists
that MMP10 also displays tumor-protective capabilities.
Koller et al. described an enhanced development of
inflammation-associated colonic dysplasia in colitis in-
duced mice lacking MMP10 based on an unremitting in-
flammation as the major cause. However no changes
mediated by MMP10 could be proven in colonic epithe-
lial cells [43]. Due to contradictory effects of MMP10
further investigations are needed to profoundly evaluate
the role and differences of MMP10 in colon cancer and
inflammatory bowel disease associated dysplasia.
As we have observed for MMP7 and MMP10, we
found that elevated abundance of serum MMP12 in
colon cancer patients is associated with a significantly
shortened overall survival. Consistently with MMP7 and
MMP10 also overexpression of MMP12 in colorectal
cancer specimen is reported [27]. However divergent
evidence exists that - opposing to MMP7 and MMP10 -
MMP12 diminishes colon cancer growth in vitro and
has a favorable impact on overall survival in colorectal
cancer patients [44]. Interestingly, Asano et al. observed
higher level of MMP12 in M0-staged patients compared
to metastasized patients in primary colorectal cancer
[27]. These antitumorigenic effects could be based on
MMP12-induced decrease of VEGF (vascular endothelial
growth factor) level as well as on an increase of Angios-
tatin level - both are known to play a crucial role in
tumor neovascularization [45]. Contrary, we observed a
higher relative serum expression of MMP12 in patients
with vascular invasion (V1-stage) compared to V0-
staged patients suggesting a tumor promoting role of
serum MMP12. Moreover, patients with single nucleo-
tide polymorphism (SNP) in the promotor region of
MMP12 display a higher risk of suffering from dissemi-
nated colorectal cancer and for stromal MMP12 expres-
sion in colorectal cancer liver metastases an association
with impaired survival is observed [46, 47]. Moreover in-
vasive and migrative potential of MMP12 is noted in
vitro [24]. Therefore MMP12 seems to exhibit both pro-
tumorigenic as well as antitumorigenic properties prob-
ably due to the fact, if MMP 12 is derived rather from
macrophages, stromal or tumor cells and the occurrence
of functional single nucleotide polymorphism (SNPs)
[44–49]. As for MMP10 until now there are no studies
assessing MMP12 expression in colon cancer patients´
sera in regard with overall survival. We suggest a tumor
promoting role of MMP12 due to impaired overall sur-
vival in colon cancer patients expressing higher serum
level of MMP12.
In summary, our results imply a significant influence
of serum MMP7, MMP10 and MMP12 in human colon
cancer dissemination with considerable impact on over-
all survival. Moreover we are the first to demonstrate
that relative serum expression of MMP10 in colon can-
cer patients is an independent prognostic determinant
for adverse prognosis. Therefore we presume the neces-
sity of measuring serum expression of MMPs to facilitate
a prediction of prognosis. The present study evinces
Table 3 Multivariate analysis (Cox proportional hazards regression model) of prognostic parameters for overall survival in colon cancer.
A MMP10 relative serum expressional ratio ≥2 is an independent prognostic marker in colon cancer patients
Patient characteristics Hazard ratio 95 % Confidence interval of relative risk p-value
Median age 1.372 0.477–3.943 0.557
Gender 1.275 0.364–4.464 0.704
UICC stage 1.081 0.232–5.027 0.921
T-stage 0.775 0.277–2.174 0.629
N-stage 1.68 0.518–5.447 0.387
M-stage 1.813 0.255–12.912 0.562
R-stage 0.673 0.112–4.033 0.665
Grading 1.127 0.405–3.137 0.820
Adjuvant chemotherapy 1.251 0.236–6.636 0.792
Anastomotic leakage 0.518 0.09–2.992 0.462
MMP7 relative serum expression ≥2 0.901 0.170–4.788 0.903
MMP10 relative serum expression ≥2 3.866 1.069–13.976 0.039
MMP12 relative serum expression ≥2 2.421 0.548–10.695 0.243
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MMP7, MMP10 and MMP12 level in a homogenous
collective of colon cancer patients´ sera to have predict-
ive significance and boosts the idea that these markers
represent essential prognostic factors and are probable
molecular targets for tailored, individualized therapeutic
approaches for prospective antitumoral strategies.
Conclusion
Upregulation of several MMPs plays a pivotal role regard-
ing tumor progression, metastatic formation and patients´
outcome likewise in colon cancer. Large studies correlat-
ing differential MMP expression in colon cancer patients´
sera are scarce. In the present study we investigated the
expression of MMP7, MMP10 and MMP12 in serum
specimens in a homogenous collective of colon cancer
patients with regard to clinicopathological characteristics
and patients´ prognosis. MMP7, MMP10 and MMP12
were significantly associated with a dismal prognosis.
Moreover, MMP10 is an independent prognostic marker
in colon cancer patients. Overexpression of MMP12 was
observed more frequently in patients with vascular inva-
sion. The findings are promising and evince the potential
of serum MMP7, MMP10 and MMP12 expression as
prognostic biomarker. The results may help to stratify pa-
tients into different risk groups. Therefore, further pro-
spective studies with a larger cohort of patients are
required.
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